Request Sample Inquiry
Artificial Intelligence in Drug Discovery Market

Artificial Intelligence in Drug Discovery Market

Artificial Intelligence in Drug Discovery Market - Global Industry Assessment & Forecast

Number Of Pages # Pages:

175

Base Year:

2021

Date

Feb - 2022

Format:

PDF XLS PPT

Report Code:

VMR-1239

Segments Covered
  • By Application Drug Optimization and Repurposing, Preclinical Testing, Others
  • By Therapeutic Look Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease, Others
  • By Region North America, Latin America, Europe, Asia Pacific, Middle East & Africa
Snapshot
Forecast YearsForecast Years: 2022 - 2028
Historical YearsHistorical Years: 2016 - 2021
Revenue 2021Revenue 2021: USD 627.1 Million
Revenue 2028Revenue 2028: USD 4,197.5 Million
Revenue CAGRRevenue CAGR (2022 - 2028): 41.5%
Fastest Growing Region Fastest Growing Region (2022 - 2028) Asia Pacific
Largest Region Largest Region (2021): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst
Artificial Intelligence in Drug Discovery Market Share

Market Synopsis:

Global Artificial Intelligence in Drug Discovery market is valued at USD 627.1 Million in 2021 and is projected to attain a value of USD 4,197.5 Million by 2028 at a CAGR of 41.5% during the forecast period, 2022–2028. In recent years, there has been an increasing push to reduce the cost of innovative drug development and production, which is likely to boost demand for Artificial Intelligence in Drug Discovery area. As per analysis, the average cost of developing a new medicine is USD 2.6 billion. This is primarily owing to the limited development testing funnel, which excludes the bulk of prospective medicines from preclinical and phase 1 trials. As a result, the pharmaceutical industry's deployment of artificial intelligence for faster, more efficient, and cost-effective drug discovery is gaining traction.

Artificial Intelligence in Drug Discovery Market Size, 2021 To 2028 (USD Million)

Factors such as the growing population, the need to expand healthcare access, the rising prevalence of chronic diseases and conditions, a physician shortage, advancements in telecommunications, increasing awareness, government support, and increasing technology adoption are all driving growth in the Artificial Intelligence in Drug Discovery market.

Additionally, widespread use by multiple businesses for the identification and screening of existing medicines for the treatment of COVID-19, the COVID-19 outbreak had a beneficial impact on the growth of artificial intelligence in the drug discovery market.

Increasing Demand for Artificial Intelligence in Drug Discovery

Another important aspect driving artificial intelligence adoption in the drug development area is the massive amounts of data generated by molecular screening and preclinical trials. The vast amount of data makes reviewing all of the scientific literature a difficult task for the scientist. Artificial intelligence can help speed up the screening process and cut down on the time it takes to study and identify drug molecule interactions and histology data in these situations. Another important aspect of AI's growing adoption in the drug discovery space is the availability of a wide range of options for carrying out standard processes like data mining and customising AI platforms. Pharmaceutical firms can benefit from breakthroughs in artificial intelligence, such as machine learning and deep learning.

On the other side, the market's expansion is being hampered by lack of data sets in the field of drug research and an insufficient supply of competent workers.

Market Segmentation:

The Global Artificial Intelligence in Drug Discovery Market can be segmented by Application, into Drug optimization and repurposing, Preclinical testing and Others. Based on Therapeutic Area, Artificial Intelligence in Drug Discovery Market can be segmented into Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease and Others. Based on Region, the Artificial Intelligence in Drug Discovery Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Below tree is interactive. You can click the nodes to get more information.

The oncology therapeutic area had the biggest revenue share in the Artificial Intelligence in Drug Discovery market, based on therapeutic area. AI is already helping to detect cancer in its early stages. Furthermore, because cancer treatments differ by patient, personalised medicine has proven to be a successful cancer therapy option. Oncologists can use artificial intelligence platforms to find genetic abnormalities and provide successful tailored treatments for their patients.

North America to Continue Dominating the Artificial Intelligence in Drug Discovery Market

The greatest market for Artificial Intelligence in Drug Discovery is North America, which includes the United States and Canada. These countries were among the first to use Artificial Intelligence in Drug Discovery and development. The United States is a key player in the North American market. Furthermore, major AI technology companies such as Microsoft, NVIDIA, IBM, Google, and Intel are based in the United States, and their substantial presence is a crucial contributor to market growth. The well-established pharmaceutical industry, a strong focus on R&D and significant investment, and the presence of globally leading pharmaceutical corporations are all further drivers. These are some of the primary elements that have contributed to this industry's big share and rapid growth rate.

USD 362.4 Million

Key Players:

Some of the players are IBM Corporation (US), Microsoft (US), and Google (US), NVIDIA Corporation (US), Atomwise, Inc. (US), Deep Genomics (Canada), Cloud Pharmaceuticals (US), Insilico Medicine (US), BenevolentAI (UK), Exscientia (UK), Cyclica (Canada), BIOAGE (US), Numerate (US), NuMedii (US), Envisagenics (US), twoXAR (US), OWKIN, Inc. (US), XtalPi (US), Verge Genomics (US), and BERG LLC (US).

The Artificial Intelligence in Drug Discovery market is segmented as follows:

Parameter Details
Segments Covered
  • Application (Drug Optimization and Repurposing, Preclinical Testing, Others)
  • Therapeutic Look (Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease, Others)
  • Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Regions & Countries Covered
  • North America - (U.S., Canada, Mexico)
  • Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
  • Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
  • Latin America - (Brazil, Argentina, Rest Of Latin America)
  • Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
Companies Covered
  • IBM Corporation (US)
  • Microsoft (US)
  • and Google (US)
  • NVIDIA Corporation (US)
  • Atomwise Inc. (US)
  • Deep Genomics (Canada)
  • Cloud Pharmaceuticals (US)
  • Insilico Medicine (US)
  • BenevolentAI (UK)
  • Exscientia (UK)
  • Cyclica (Canada)
  • BIOAGE (US)
  • Numerate (US)
  • NuMedii (US)
  • Envisagenics (US)
  • twoXAR (US)
  • OWKIN Inc. (US)
  • XtalPi (US)
  • Verge Genomics (US)
  • and BERG LLC (US)
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis

The Artificial Intelligence in Drug Discovery market is tabulated as follows:

Artificial Intelligence in Drug Discovery Market Anticipated to Reach USD 4,197.5 Million by 2028
The Artificial Intelligence in Drug Discovery Market is expected to reach USD 4,197.5 Million by 2028, growing at a Compound Annual Growth Rate (CAGR) of 41.5% from 2022 to 2028. Factors such as the increasing adoption of cloud-based services & applications, the rising need for controlling the drug ...
FAQ
Frequently Asked Question
  • The global Artificial Intelligence in Drug Discovery valued at USD 627.1 Million in 2020 and is expected to reach USD 4,197.5 Million in 2028 growing at a CAGR of 41.5%.

  • The prominent players in the market are IBM Corporation (US), Microsoft (US), and Google (US), NVIDIA Corporation (US), Atomwise, Inc. (US), Deep Genomics (Canada), Cloud Pharmaceuticals (US), Insilico Medicine (US), BenevolentAI (UK), Exscientia (UK), Cyclica (Canada), BIOAGE (US), Numerate (US), NuMedii (US), Envisagenics (US), twoXAR (US), OWKIN, Inc. (US), XtalPi (US), Verge Genomics (US), and BERG LLC (US).

  • The market is project to grow at a CAGR of 41.5% between 2021 and 2028.

  • The driving factors of the Artificial Intelligence in Drug Discovery include

    • Increasing Demand for Artificial Intelligence in Drug Discovery

  • North America was the leading regional segment of the Artificial Intelligence in Drug Discovery in 2020.